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Objectives: to compare the clinical outcome of in situ and reversed bypass grafting.
Design: multicentre, prospective, non-randomised study.
Patients and methods: five-hundred patients with an in situ graft and 955 patients with a reversed graft were compared
regarding graft occlusion, the need for graft revision, and limb salvage.
Results: two-year assisted primary patency of femoropopliteal bypass procedures was 82% for in situ and 82% for
reversed grafts. The corresponding hazard ratio (HR) for occlusion was 1.27 (95% CI 0.91–1.77). The 2-year assisted
primary patency of femorocrural bypass procedures was 69% for in situ vs. 70% for reversed grafts. The corresponding
HR was 1.13 (95% CI 0.73–1.75). Adjustment for relevant baseline variables did not change the results. More
reinterventions were needed to maintain integrity and patency of the in situ graft especially in crural bypasses. No
differences in limb salvage rates were seen.
Conclusions: reversed and in situ vein grafts have similar patency and limb salvage rates for both femoropopliteal and
femorocrural bypass procedures. The in situ graft needs more secondary interventions.
Key Words: Vascular patency; Prospective study; Infrainguinal surgery; In situ bypass; Reversed saphenous vein bypass.
Introduction reversed vein grafting.5–9 In the Scandinavian countries
the reversed vein bypass has been almost abandoned
Widespread experience has proven the autologous in favour of the in situ technique and PTA.10 However,
several randomised studies have failed to show asaphenous vein to be the best graft material for infra-
inguinal bypass. Whether the vein should be reversed significant difference between the two techniques.11–14
A problem is that these studies were rather small and,or left in situ is a matter of debate. The reversed
method has become well established in the last 50 hence, do not allow robust conclusions. We therefore
analysed the patency data on reversed and in situyears as a procedure with good durable results. Many
still consider this time-honoured technique the ‘‘gold- bypasses collected within the Dutch BOA Study, a
large randomised clinical trial, comparing the efficacystandard’’ for infrainguinal arterial reconstruction.1–4
The in situ technique is not a new concept, but has of oral anticoagulation (INR 3.0–4.5) and aspirin (80 mg
daily).15regained popularity during the last 15 years with the
development of safe and reliable methods of valve
disruption. Based on favourable comparisons with
historic controls of the reversed bypass, and the theor-
etical (but not proven) advantages of improved pre- Patients and Methods
servation of endothelium, better haemodynamics and
compliance characteristics, a number of authors have All patients included in the Dutch BOA Study in
whom the greater saphenous vein was used as graftconcluded that the in situ vein grafting is superior to
material for infrainguinal bypass surgery were eligible
for the present study. The BOA Study was approved
* Please address all correspondence to: J. A. Lawson, BOA Trial by the Ethics Committees of all participating hospitalsOffice, Bolognalaan 30, 3584 CJ Utrecht, The Netherlands.
† Participating investigators are listed in the appendix. and by the Dutch Health Insurance Council. All
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patients who were enrolled in the study gave informed Results
written consent. Between April 1995 and March 1998
Demographic and clinical characteristics of the patientsa total of 2645 patients were randomised. For each
in both groups, subdivided according to femoro-patient vascular history, risk factors, clinical category
popliteal and femorocrural bypasses are shown inof limb ischaemia, medication and operation details
Table 1. The two groups requiring femoropoplitealwere recorded. All patients with an in situ saphenous
bypass were similar with regard to most baselinevein graft (n=500) and all patients with a reversed
characteristics except for the site of the distal ana-greater saphenous vein graft (n=955) were selected
stomosis (more below-knee in situ grafts) and thefor the present study. The operative technique to be
angiographic run-off (worse in the in situ group). Theused within the trial was left to the discretion of the
two groups requiring femorocrural bypass were alsosurgeon. In 15 of the 77 participating hospitals the in
similar; however, there were more previous vascularsitu graft was predominantly used. In 24 hospitals
interventions in the reversed group and more patientsonly the reversed method was used for infrainguinal
within this group were operated on for critical isch-bypass. Vascular surgeons at 20 of the 53 participating
aemia than in the group with in situ grafts. Therehospitals who included patients with femorocrural
was no difference in mean hospital stay between thebypasses, preferred the in situ method for this pro-
reversed and the in situ group: 13.9 versus 13.4 dayscedure.
for femoropopliteal bypass procedures, and 20.6 ver-Patients were seen 3 and 6 months postoperatively
sus 20.3 days for femorocrural bypasses. The allocatedand every 6 months thereafter. The primary endpoint
postoperative antithrombotic treatment (oral anti-was bypass occlusion, which was mostly confirmed
coagulants of aspirin) was well balanced between theby duplex scanning or angiography. Adverse patient
groups. The mean follow-up of all included patientsoutcomes including death, major amputation of the
was 12.6 months (reversed: 13.4, in situ: 11.3). Inoperated limb, graft failure, and need for graft revision
patients with a femoropopliteal bypass eventuallywere recorded relative to graft type and time after
14.7% (159/1082) of the grafts occluded; 13.9% (108/the primary grafting procedure. Graft patency was
775) of the reversed grafts and 16.6% (51/307) of thedetermined by physical examination, a decrease in ABI
in situ grafts. In the patients with a femorocruraland duplex scanning. Cumulative primary, assisted
bypass 21.9% (82/373) of the grafts occluded; 21.7%primary and secondary patency and limb salvage rates
(39/180) of the reversed grafts and 22.2% (43/193) ofwere calculated by the Kaplan–Meier survival analysis
the in situ grafts.according to the Ad Hoc Committee on Reporting
Hazard ratios (HRs) were calculated for all baselineStandards. Primary patency was defined as un- characteristics. Variables predictive for occlusion of
interrupted patency without any procedures per- femoropopliteal bypasses were female gender: HR 1.54
formed on the graft or on its anastomoses. If minor (95% CI 1.13–2.12); poor angiographic run-off: HR
graft revisions, such as ligation of arteriovenous fistula, 1.60 (95% CI 1.14–2.24) and clinical signs of critical
incision of residual valve leaflets, or PTA of graft ischaemia: HR 1.70 (95% CI 1.24–2.33). No predictive
stenosis or adjacent artery, were necessary to avoid variables were found for occlusion of femorocrural
graft occlusion, the graft was classified under assisted bypasses.
primary patency. If graft patency was restored after
occlusion by thrombectomy or thrombolysis and even-
tually completed with PTA or a minor graft re- Primary patency
placement the graft was classified under secondary
patency. Patency rates for in situ and reversed grafts In femoropopliteal bypass the 2-year primary patency
and limb salvage rates were compared with the log rate was 67% for in situ and 74% for reversed veins,
rank test (SPSS Inc., Chicago, IL, statistical package). p=0.02 (Figure 1). The corresponding HR for loss of
The risk of bypass occlusion, the need for graft revision, primary patency (occlusion or need for secondary
and the risk for major amputation were also compared intervention) was 1.51 (95% CI 1.15–1.98). In fem-
by means of hazard ratios with corresponding 95% orocrural bypass the 2-year primary cumulative pat-
confidence intervals. Because the study design did not ency was for in situ (52%) and for reversed (63%), p=
use random assignment according to grafting tech- 0.04. The corresponding HR for loss of primary patency
nique, we used multivariate Cox regression analysis was 1.50 (95% CI 1.03–2.18). Adjustment for baseline
to adjust for possible incomparabilities between the variables did not change the significant greater risk of
groups. We analysed the data separately for fem- occlusion or need for secondary intervention in the in
situ femoropopliteal and femorocrural bypass group.oropopliteal and femorocrural bypasses.
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Table 1. Patient demographics and clinical characteristics.
Femoropopliteal bypass Femorocrural bypass
in situ reversed in situ reversed
No. of patients 307 775 193 180
Above-knee anastomosis 30% 43% — —
Pedal anastomosis — — 12.4% 5.6%
Mean age 69.9 69.6 73.8 72.3
Proportion male 68% 66% 61% 68%
Hypertension 39.1% 38.8% 40.4% 38.9%
Hyperlipidaemia 17.0% 17.0% 10.4% 15.6%
Diabetes 24.4% 22.7% 36.3% 35.6%
Smoking 55.2% 59.6% 42.0% 43.3%
Prior MI 16.0% 16.4% 19.2% 16.1%
Prior CVA/TIA 12.7% 9.4% 15.9% 13.9%
Prior vascular intervention* 44.0% 40.7% 33.2% 45.0%
Indication for surgery
Claudication 54.7% 55.7% 24.4% 16.1%
Limb salvage 45.3% 44.3% 75.6% 83.9%
Angiographic run-off*
Good 32.2% 41.5% — —
Fair 36.8% 36.7% — —
Poor 30.0% 21.8% — —
Mean ankle/brachial ratio 0.54 0.57 0.43 0.50
* Previous vascular intervention means any vascular procedure.
— Not applicable.
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Fig. 1. Lifetable showing primary patency for reversed bypass (—) and in situ bypass (---) subdivided for femoropopliteal bypass (fempop)
and femorocrural bypass (femcrur). Log rank test: fempop: p=0.02, femcrur: p=0.04.
Assisted primary patency 2). In femorocrural bypass the 2-year assisted primary
cumulative patency was 69% for in situ and 70% for
In femoropopliteal bypasses the 2-year assisted prim- reversed veins, p=0.68. The corresponding HR for
occlusion was 1.13 (95% CI 0.73–1.75). Again ad-ary patency rate was 82% for in situ and 82% for
reversed, p=0.14 (Fig. 2). The corresponding HR for justment for variables that were unequally distributed
(previous vascular intervention and preoperative clin-loss of assisted primary patency (occlusion) was 1.51
(95% CI 0.90–1.77). Adjustment for the identified risk ical stage) only had a marginal influence on the results
(Table 2).factors did not change these results significantly (Table
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Fig. 2. Lifetable showing assisted primary patency for reversed bypass (—) and in situ bypass (---) subdivided for femoropopliteal bypass
(fempop) and femorocrural bypass (femcrur). Log rank test: fempop p=0.14, femcrur p=0.68
Table 2. Assisted primary cumulative patency. Adjustment for predictive variables
for femoropopliteal and femorocrural graft occlusion.
Assisted primary patency
Variable HR 95% CI p
Femoropopliteal bypass
In situ graft 1.27 0.91–1.77 0.17
Adjusted for gender 1.29 0.92–1.80 0.14
Adjusted for clinical stage 1.25 0.89–1.75 0.19
Adjusted for run-off 1.22 0.87–1.72 0.25
Adjusted for distal anastomosis 1.22 0.87–1.71 0.25
Adjusted for all above 1.21 0.86–1.70 0.27
Femorocrural bypass
In situ graft 1.13 0.73–1.75 0.58
Adjusted for clinical stage 1.12 0.72–1.74 0.60
Adjusted for previous vascular intervention 1.09 0.70–1.69 0.71
Adjusted for all above 1.08 0.69–1.68 0.74
Secondary patency Graft revision
The 2-year secondary patency in femoropopliteal by- In the total group of patients, 231 secondary inter-
ventions were necessary to maintain integrity orpass was 85% for in situ and 84% for reversed veins,
p=0.59 (Fig. 3). In femorocrural bypass the 2-year patency of the graft: 124 in the group of patients with
an in situ graft (n=500) and 107 in the group with acumulative secondary patency was 74% for in situ and
71% for reversed veins, p=0.72. The HR for occlusion reversed graft (n=955). The numbers are shown in
Table 3, stratified for femoropopliteal bypass and fem-was for femoropopliteal bypasses 1.11 (CI 95% 0.76–
1.60 and for femorocrural bypasses 0.91 (CI 95% 0.58– orocrural bypass. Significantly more secondary inter-
ventions were necessary in the in situ group, especially1.46). After adjustment for relevant baseline variables
these results were essentially the same. in long (femorocrural) bypasses. Three interventions
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Fig. 3. Lifetable showing secondary patency for reversed bypass (—) and in situ bypass (---) subdivided for femoropopliteal bypass
(fempop) and femorocrural bypass (femcrur). Log rank test: fempop p=0.59, femcrur p=0.72
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Fig. 4. Lifetable showing limb salvage for reversed bypass (—) and in situ bypass (---) subdivided for femoropopliteal bypass (fempop)
and femorocrural bypass (femcrur). Log rank test: fempop p=0.31, femcrur p=0.55
were necessary for graft infection (one in situ and two 1.41 (95% CI 0.71–2.79) for femoropopliteal bypasses
and 1.20 (95% CI 0.65–2.25) for femorocrural bypasses.reversed veins).
In the ten patients with a reversed graft with a pedal
anastomosis no graft occlusion occurred and no major
amputations were necessary. In the group of twenty-
Limb salvage four patients with an in situ graft with a pedal ana-
stomosis six occlusions occurred and five major am-For analysis of limb salvage, only patients with critical putations were needed.ischaemia at baseline were selected. The 2-year limb
salvage rate for patients with a femoropopliteal bypass
(n=496) was 89% for in situ and 92% for reversed Discussion
veins, p=0.31 (Fig. 4). The 2-year limb salvage rate
for patients with a femorocrural bypass (n=312) was The results of this study indicate that claims for super-
iority of in situ grafts over reversed grafts in fem-82% for in situ and 85% for reversed veins, p=0.31.
The HR for major amputation (in situ vs. reversed) is oropopliteal and femorocrural bypass surgery are
Eur J Vasc Endovasc Surg Vol 18, August 1999
J. A. Lawson et al.154
Table 3. Secondary interventions to maintain integrity or patency of infrainguinal
bypass.
Intervention in situ reversed
Femoropopliteal bypass n=307 n=775
Suturing/closure fistula 10 4
PTA 18 24
Revision 16 40
Thrombolysis 0 3
Thrombectomy 8 8
Not specified 3 6
Total 55 85
Femorocrural bypass n=193 n=180
Suturing/closure fistula 12 1
PTA 17 6
Revision 26 10
Thrombolysis 1 0
Thrombectomy 9 5
Not specified 4 0
Total 69 22
unjustified. In terms of assisted primary patency, has improved the outcome substantially, hence com-
parison with historic controls is biased. In other non-secondary patency and limb salvage, we observed no
statistically significant differences. The corresponding randomised series a clear selection bias was introduced
because comparison was made with a second-choicerisk for graft occlusion was no different for either
technique. The primary patency is both dependent on reversed graft (for example spliced or ectopic veins)
which was only used if in situ grafting was not feas-the occlusion rate and the occurrence of graft problems
that need minor graft revisions to avoid graft occlusion. ible.21 In the current study only reversed greater sa-
phenous vein grafts were selected for comparison withThe present study showed that the primary patency
in femoropopliteal and femorocrural bypass surgery in situ grafts, often as first choice.
Besides these favourable comparisons with historicis in favour of reversed bypass grafting. The risk of
occlusion or secondary intervention is greater for the controls or second choice grafts a few theoretical ad-
vantages of the in situ graft have been suggested. Thein situ bypass. The reason for this difference is the
proportion of secondary interventions needed after in vein utilisation rate using the in situ technique might
be higher because smaller calibre veins can be used.5situ operation to maintain integrity and patency of the
graft. In two of the randomised trials13,14 and several studies
about the influence of graft diameter on graft pat-We compared two parallel study groups in whom
the bypass technique was non-randomly allocated. ency22–24 smaller veins performed very badly, in-
dependently of which kind of grafting was applied.Hence the two groups differed to some extent with
regard to the risk of graft occlusion. However, if we Thus, it may be technically possible to utilise smaller
veins by the in situ technique because of a betteradjusted the crude hazard ratios for the variables
predictive for occlusion, we found essentially the same match to the recipient artery, but the results make the
employment of such small veins questionable for eitherresults. We therefore conclude that baseline differences
did not play a major role in our study. Seventy-seven technique. Moreover, utilisation rates are only valid if
all patients who require infrainguinal bypass surgeryhospitals from all over The Netherlands participated
in this investigation; in 30% of hospitals, only reversed are investigated, not just those with an intact ipsilateral
greater saphenous vein. A major disadvantage of thegrafts were used, whereas in 50% in situ grafts were
used, if a femorocrural bypass was needed. This in situ technique is that use of an ipsilateral saphenous
vein is mandatory. Leather et al. reported, on theheterogeneity reflects current surgical practice in The
Netherlands. The findings of the present study are to biggest series of in situ bypass operations, that about
30% of patients who needed a venous bypass werea large extent in accordance with the results of four
randomised trials11–14 and several non-randomised operated on with the (partially) reversed method be-
cause a complete in situ bypass procedure was im-comparative studies.16–18 Some authors who have
claimed superiority for the in situ graft compared the possible.6 In one of the randomised studies 37% of the
candidates for randomisation were excluded becausepatency rates of this graft type with a non-con-
temporaneous series of the reversed bypass op- it was impossible to perform an in situ graft; 30% of
these patients underwent a reversed vein bypass.11 Inerations.19,20 The evolution of the reversed technique
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our study we did not obtain data that allowed analysis ipsilateral greater saphenous vein is missing. If the
ipsilateral greater saphenous vein is available, theof vein utilisation rates for either the reversed or in
present study has shown that neither technique givessitu bypass technique.
significantly better assisted primary patency, sec-In the in situ technique preservation of the endo-
ondary patency rates, or limb salvage. Relatively morethelial lining by keeping the vasa vasorum intact
secondary interventions are needed to maintain theshould lead to a less thrombogenic flow surface and
integrity and patency of the in situ graft, especiallyimproved fibrinolytic activity. There is little ex-
after femorocrural bypass surgery. A large-scale ran-perimental evidence to support this theory.25,26 The
domised study with special emphasis on graft sur-extent of de-endothelialisation caused by valve strip-
veillance and a strict strategy for treating graft stenosespers is much higher than previously believed.26–29 Ex-
is needed to give a definitive answer.perimental studies have shown no difference in the
development of intimal hyperplasia related to grafting
technique. Preservation of adventitia and vasa va-
Referencessorum had no biologic effect on the development of
the same intimal changes in the midsection of reversed
1 Taylor LM, Jr, Edwards JM, Phinney ES, Porter JM. Reversed
and in situ vein grafts.30 Clinical evidence for less vein bypass to infrapopliteal arteries. Modern results are superior
to or equivalent to in-situ bypass for patency and for veinendothelial damage in the in situ graft should be a
utilization. Ann Surg 1987; 205: 90–97.smaller incidence of intrinsic graft stenosis caused by 2 Mills JL, Taylor SM. Results of infrainguinal revascularization
intimal hyperplasia. In his thesis, Idu presented an with reversed vein conduits: a modern control series. Ann Vasc
Surg 1991; 5: 156–162.extensive review of surveillance studies with duplex
3 Neale ML, Graham JC, Lane RJ, Cheung DS, Appleberg M.scanning together with his own results of a Dutch The influence of graft type on patency of infrainguinal arterial
multicentre study. Both studies showed that the in- bypass grafts. J Am Coll Surg 1994; 178: 155–163.
4 Taylor LM, Jr, Phinney ES, Porter JM. Present status ofcidence of stenotic lesions was similar for the in situ
reversed vein bypass for lower extremity revascularization. Jand the reversed bypass.31 In a multivariate analysis Vasc Surg 1986; 3: 288–297.
investigating 128 in situ grafts and 172 non-in situ 5 Leather RP, Shah DM, Chang BB, Kaufman JL. Resurrection
of the in situ saphenous vein bypass. 1000 cases later [seegrafts the grafting technique was not a predictive
comments]. Ann Surg 1988; 208: 435–442.
variable for graft stenosis. Only a small graft diameter 6 Shah DM, Darling RC III, Chang BB et al. Long-term results
of in situ saphenous vein bypass. Analysis of 2058 cases. Ann(<3.5 mm) was a significant predictor for graft stenosis
Surg 1995; 222: 438–446; discussion 446–448.regardless of which grafting technique was used. In
7 Fogle MA, Whittemore AD, Couch NP, Mannick JA. A com-
the present study the number of reinterventions for parison of in situ and reversed saphenous vein grafts for infra-
inguinal reconstruction. J Vasc Surg 1987; 5: 46–52.graft stenosis were significantly higher for the in situ
8 Connolly JE. In situ saphenous vein bypass: 1962 to 1987. Amtechnique. An explanation for this difference in results
J Surg 1987; 154: 2–10.
is perhaps the fact that the BOA Study is a large 9 Gruss JD, Bartels D, Vargas H, Karadedos C, Schlechtweg
B. Arterial reconstruction for distal disease of the lower ex-multicentre study, with participants who have a great
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13 Moody AP, Edwards PR, Harris PL. In situ versus reversedanastomosis of artery and venous graft. Theoretically,
femoropopliteal vein grafts: long-term follow-up of a pro-
this should lead to better haemodynamic flow char- spective, randomized trial. Br J Surg 1992; 79: 750–752.
14 Watelet J, Soury P, Menard JF et al. Femoropopliteal bypass:acteristics, but several haemodynamic studies have not
in situ or reversed vein grafts? Ten-year results of a randomizedshown any improvement in performance.32,33 Studies prospective study. Ann Vasc Surg 1997; 11: 510–519.
which measured compliance of the graft after im- 15 Tangelder MJD, Eikelboom BC, Lawson JA, Algra A. Pre-
vention of occlusion following peripheral bypass surgery usingplantation found no difference related to grafting tech-
oral anticoagulants or acetylsalicylic acid: a randomized com-nique.34,35 parison with the Dutch BOA study. Ned Tijdschr Geneeskd 1995;
In summary we found that the in situ technique is 139: 1504–1506.
16 Comparative evaluation of prosthetic, reversed, and in situ veinnot the Holy Grail that some proponents would like
bypass grafts in distal popliteal and tibial–peroneal re-us to believe. In about 30% of cases, in situ and reversed vascularization. Veterans Administration Cooperative Study
Group 141. Arch Surg 1988; 123: 434–438.techniques are not equally applicable, because the
Eur J Vasc Endovasc Surg Vol 18, August 1999
J. A. Lawson et al.156
17 Ricci MA, Graham AM, Symes JF. Comparison of in-situ and van Baal, J. W. van den Heuvel); Ziekenhuis Amstel-
reversed saphenous vein grafts for infrageniculate bypass. Can
veen (60; P. J. van Aken, J. A. Lawson); AcademischJ Surg 1990; 33: 216–220.
18 Sasajima T, Kubo Y, Kokubo M, Izumi Y, Inaba M. Comparison Medisch Centrum Amsterdam (79; R. Balm, M. J. H. M.
of reversed and in situ saphenous vein grafts for infragenicular Jacobs, C. Kox, D. A. Legemate, S. M. M. van Ster-
bypass: experience of two surgeons. Cardiovasc Surg 1993; 1:
kenburg); Academisch Ziekenhuis Vrije Universiteit38–43.
19 Leather RP, Powers SR, Karmody AM. Reappraisal of the in Amsterdam (16; A. J. C. Mackaay, J. A. Rauwerda,
situ saphenous vein arterial bypass: its use in limb salvage. E. G. J. Vermeulen, C. van der Waal); Slotervaart-
Surgery 1979; 85: 453–461.
ziekenhuis Amsterdam (9; B. J. Dwars, T. O. M. Nagy);20 Bergmark C, Johansson G, Olofsson P, Swedenborg J. Femoro-
popliteal and femorodistal bypass: a comparison between in situ St. Lucas Ziekenhuis Amsterdam (15; A. Voorwinde);
and reversed technique. J Cardiovasc Surg (Torino) 1991; 32: Ziekenhuiscentrum Apeldoorn (9; P. H. Rutgers);117–120.
Ziekenhuis Rijnstate Arnhem (44; T. I. F. M. Bloemen,21 Gupta AK, Bandyk DF, Cheanvechai D, Johnson BL. Natural
history of infrainguinal vein graft stenosis relative to bypass W. H. A. Govaert, I. M. C. Janssen, J. H. G. Klinkenbijl,
grafting technique. J Vasc Surg 1997; 25: 211–220. W. R. de Vries); Wilhelmina Ziekenhuis Assen (5;22 Towne JB, Schmitt DD, Seabrook GR, Bandyk DF. The effect
J. A. G. de Groot, H. A. M. Heikens); Medisch Centrumof vein diameter on patency of in situ grafts. J Cardiovasc Surg
(Torino) 1991; 32: 192–196. Molendael Baarn (22; M. S. Verweij); Stichting Zieken-
23 Varty K, London NJ, Brennan JA, Ratliff DA, Bell PR. huis Lievensberg Bergen op Zoom (2; T. H. A. Bikkers);Infragenicular in situ vein bypass graft occlusion: a multivariate
risk factor analysis. Eur J Vasc Surg 1993; 7: 567–571. Ziekenhuis Gooi-Noord Blaricum (18; J. Greebe, G. T.
24 Wengerter KR, Veith FJ, Gupta AK, Ascer E, Rivers SP. The); Ignatiusziekenhuis Breda (23; H. G. W. de Groot,
Influence of vein size (diameter) on infrapopliteal reversed vein
R. A. E. Wirtz); Ziekenhuis De Baronie Breda (131;graft patency. J Vasc Surg 1990; 11: 525–531.
25 Bush HL, Jr, Graber JN, Jakubowski JA et al. Favorable balance R. M. P. H. Crolla, F. J. M. van Geloven, G. A. M. Kokke,
of prostacyclin and thromboxane a2 improves early patency of P. M. Raams, W. J. van Remortel); IJsselland Ziekenhuis
human in situ vein grafts. J Vasc Surg 1984; 1: 149–159.
Capelle a/d IJssel (35; I. Dawson, C. L. Koppert);26 Cambria RP, Megerman J, Abbott WM. Endothelial pre-
servation in reversed and in situ autogenous vein grafts. A Reinier de Graaf Gasthuis Delft (89; W. B. J. Jansen, J.
quantitative experimental study. Ann Surg 1985; 202: 50–55. Koning); Gemini Ziekenhuis Den Helder (9; J. J. M.27 Sayers RD, Watt PA, Muller S, Bell PR, Thurston H. Struc-
Jutte, H. D. Tjeenk Willink); Stichting Deventer Zieken-tural and functional smooth muscle injury after surgical pre-
paration of reversed and non-reversed (in situ) saphenous vein huizen Deventer (19; P. J. van Elk, D. van Lent);
bypass grafts. Br J Surg 1991; 78: 1256–1258. Merwedeziekenhuis Dordrecht (3; J. de Gruyl, M. T. C.28 Boyd JH, Stevens R, Havey A, Silver D. Intimal integrity and
Hoedt, P. R. Schu¨tte); Catharina Ziekenhuis Eindhovenfibrinolytic potential of reversed and in situ vein grafts. J Vasc
Surg 1987; 5: 614–621. (84; J. Buth, Ph. W. M. Cuypers, J. M. M. P. H. Herman,
29 Storm FK, Gierson ED, Sparks FC, Barker WF. Autogenous H. J. T. Rutten); Diaconessenhuis Eindhoven (62; W. J.vein bypass grafts: biological effects of mechanical dilatation
and adventitial stripping in dogs. Surgery 1975; 77: 261–267. Prakken); Medisch Spectrum Twente Enschede (77;
30 Segers MJ, Moll FL, v.d. Molengraft FJ, Klopper PJ. Intimal R. J. van Det, R. H. Geelkerken, H. J. Mulder, P. de
hyperplasia in reversed and in situ vein grafts: an intra-individual
Smit); St. Anna Ziekenhuis Geldrop (38; P. R. M. Decanine study. J Invest Surg 1994; 7: 159–165.
31 Idu MM. Surveillance of infrainguinal autologous vein bypasses. Bevere, F. Th. P. M. van der Linden); Oosterschelde-
Thesis/Dissertation, 1998. ziekenhuizen Goes (2; H. Bruins Slot, A. J. de Nie);
32 Beard JD, Lee RE, Aldoori MI, Baird RN, Horrocks M. Does
Groene Hart Ziekenhuis Gouda (19; B. J. L. Kothuis,the in situ technique for autologous vein femoropopliteal bypass
offer any hemodynamic advantage? J Vasc Surg 1986; 4: 588–594. J. C. Melse); Bronovo Ziekenhuis ’s-Gravenhage (59;
33 Gannon MX, Simms MH, Goldman M. Does the in situ tech- A. B. B. van Rijn, H. J. Smeets); Rode Kruis Ziekenhuisnique improve flow characteristics in femoropopliteal bypass? J
’s-Gravenhage (2; J. H. Allema, P. J. Breslau); WesteindeVasc Surg 1986; 4: 595–599.
34 Cambria RP, Megerman J, Brewster DC et al. The evolution of Ziekenhuis ’s-Gravenhage (13; J. C. A. de Mol van
morphologic and biomechanical changes in reversed and in-situ Otterloo, A. C. de Vries); Ziekenhuis Leyenburgvein grafts. Ann Surg 1987; 205: 167–174.
’s-Gravenhage (66; C. M. A. Bruijninckx, B. Knippen-35 Beard JD, Fairgrieve J. Compliance changes in in-situ femoro-
popliteal bypass vein grafts. Br J Surg 1986; 73: 196–199. berg, J. C. Sier); Academisch Ziekenhuis Groningen
(37; J. J. A. M. van den Dungen, J. Oskam, R. van
Accepted 22 February 1999
Schilfgaarde, E. L. G. Verhoeven); Martini Ziekenhuis
Groningen (30; H. R. van Dop, A. J. Julius, A. van der
Tol); Kennemer Gasthuis locatie Deo Haarlem (12;
E. J. Boerma, J. A. R. Coosemans); Kennemer GasthuisAppendix
locatie Elisabeth Haarlem (10; H. L. F. Brom, A. Jansen,
A. R. Koomen); Ziekenhuis St. Jansdal HarderwijkParticipating centres (with number of patients ran-
(22; W. L. Akkersdijk, A. C. van der Ham, A. K. Marck,domised and principal investigators): Medisch Cen-
M. Scheuer); De Wever Ziekenhuis Heerlen (20;trum Alkmaar (21; P. J. van den Akker, H. A. van Dijk,
R. W. Meijer); Twenteborg Ziekenhuis Almelo (20; J. G. E. C. M. Bollen, R. J. Th. J. Welten); Streekziekenhuis
Eur J Vasc Endovasc Surg Vol 18, August 1999
The Myth of the In Situ Graft 157
Midden Twente Hengelo (24; P. van der Sar); Bosch M. R. H. M. van Sambeek, H. van Urk); Ikazia Zieken-
huis Rotterdam (56; R. U. Boelhouwer, H. F. Veen);Medicentrum locatie Groot Ziekengasthuis ’s-Hertogen-
bosch (22; J. Wever, F. G. J. Willekens, R. J. de Wit); St. Clara Ziekenhuis Rotterdam (21; J. M. Hendriks,
A. A. E. A. de Smet, T. I. Yo); St. Franciscus GasthuisBosch Medicentrum locatie Willem-Alexander Zieken-
huis ’s-Hertogenbosch (60, R. M. M. van Loenhout, Rotterdam (31; W. B. van Gent, A. J. H. Kerver, C. H. A.
Wittens); Maaslandziekenhuis Sittard (62; A. G. M.T. J. M. J. Schiphorst, J. C. Wissing); Carolus-
Liduina Ziekenhuis ’s-Hertogenbosch (22; I. P. T. van Hoofwijk, W. H. V. M. L’Ortije, H. J. G. Stroeken);
Merwedeziekenhuis Sliedrecht (10; P. J. Mouthaan);Bebber, S. Bouwer, E. J. Carol, J. H. Duppen, F. T. T.
Liem); Ziekenhuis Hilversum (46; F. R. S. van Asperen St. Elisabeth Ziekenhuis Tilburg (85; D. P. van Berge
Henegouwen, J. C. Breek, J. F. Hamming); Tweestedende Boer, N. A. Koedam); Ziekenhuis Bethesda Hooge-
veen (1; H. P. Dahler); Westfries Gasthuis Hoorn (103; Ziekenhuis Tilburg (100; S. J. Brenninkmeijer, G. P. Ger-
ritsen, S. E. Kranendonk); Academisch ZiekenhuisD. L. Brands, M. W. C. de Jonge, J. W. D. de Waard);
Medisch Centrum Leeuwarden (38; D. C. Busman, R. Utrecht (66; J. D. Blankensteijn, B. C. Eikelboom,
B. H. P. Elsman, R. W. H. van Reedt Dortland, J. J. F.Leemans, J. A. Zijlstra); Academisch Ziekenhuis Lei-
den (25; G. J. M. Akkersdijk, J. M. van Baalen, J. H. van Steijling, Th. J. M. V. van Vroonhoven); Ziekenhuis
Overvecht Utrecht (54; B. C. V. M. Disselhoff); St. Jo-Bockel, G. W. H. Schurink); Diaconessenhuis Leiden
(21; B. J. Hornstra, H. Stigter); Rijnland Ziekenhuis seph Ziekenhuis Veghel (36; C. J. Broers, H. A. P. A. de
Geus); St. Joseph Ziekenhuis Veldhoven (24; M. H. M.Leiderdorp (12; S. A. da Costa, J. Dubbeld, P. A. Neijen-
huis, J. F. W. B. Rijksen); IJsselmeer Ziekenhuizen Lely- Bender, J. A. Charbon, Th. J. van Straaten); St. Maartens
Gasthuis Venlo (8; P. F. Verhagen); Holy Ziekenhuisstad (8; J. E. L. Cremers); Academisch Ziekenhuis
Maastricht (72; P. J. E. H. M. Kitslaar, J. H. M. Tordoir); Vlaardingen (57; E. R. Snijder); Streekziekenhuis Kon-
ingin Beatrix Winterswijk (2; A. A. Vafi); HofpoortSt. Antonius Ziekenhuis Nieuwegein (6; F. L. Moll,
H. D. W. M. van de Pavoordt, R. P. Tutein Nolthenius); Ziekenhuis Woerden (26; E. Bakker, W. van Eesteren);
Kennemer Gasthius locatie Zeeweg IJmuiden (3; J. J.Academisch Ziekenhuis Nijmegen (41; A. P. M. Boll,
F. G. M. Buskens, J. A. van der Vliet); Canisius-Wilhel- Petit); Stichting Ziekenhuis De Heel Zaandam (2; R. A.
Cohen, R. P. Strating); Streekziekenhuis Zevenaar (33;mina Ziekenhuis Nijmegen (71; W. B. Barendregt,
J. A. M. Hoogbergen, L. A. A. van Knippenberg, R. F. de Haan, P. E. Reenalda, C. Sieswerda, J. van
Wijk); ’t Lange Land Ziekenhuis Zoetermeer (8; M. T.A. G. A. Spelde); Waterland Ziekenhuis Purmerend
(67; Th. A. A. van den Broek, G. A. Vos); St. Laurentius Sjer, L. J. J. P. Speetjens); Het Nieuwe Spittaal Zutphen
(15; R. H. Schreve); St. Sophia Ziekenhuis Zwolle (41;Ziekenhuis Roermond (11; E. F. A. de Haan, C. M.
Nuyens); Academisch Ziekenhuis Dijkzigt Rotterdam P. J. G. Jo¨rning, M. C. Kerdel); Ziekenhuis De Weezen-
landen Zwolle (36; A. M. Blomme, E. A. Kole).(42; L. M. C. van Dortmond, N. A. J. Dubois,
Eur J Vasc Endovasc Surg Vol 18, August 1999
